Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison

Autor: Chi Duc Nguyen, Nicolas Cohen, Bruno Fautrel, Jean-Hugues Salmon, Elisabeth Gervais, Guy Baudens, Céline Labadie, Eric Houvenagel, Maeva Kyheng, Pascal Richette, Isabelle Chary-Valckenaere, X. Deprez, Thao Pham, Pascal Claudepierre, Benoît Flachaire, René-Marc Flipo, Corinne Miceli-Richard, Philippe Dieudé, Peggy Philippe, Christophe Richez, Laurent Marguerie, Damien Loeuille, Pierre Lafforgue, Jérémie Sellam, N. Segaud, Jean-Guillaume Letarouilly, Florence Tubach, Marie-Hélène Guyot

Publikováno v: Rheumatology
Rheumatology, Oxford University Press (OUP), 2021, 60 (6), pp.2773-2782. ⟨10.1093/rheumatology/keaa710⟩
Rheumatology, 2021, 60 (6), pp.2773-2782. ⟨10.1093/rheumatology/keaa710⟩

Objectives To evaluate the characteristics of patients (pts) with PsA treated by ustekinumab (UST) or secukinumab (SEK) and to compare real-world persistence of UST and SEK in PsA. Methods In this retrospective, national, multicentre cohort study, pt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17ec649463308542556b4e73424d8943
https://hal.archives-ouvertes.fr/hal-03176959/document